How is the Pharma Industry expanding to better integrate data into their practices?

Recently, we sat down with Data Driven Drug Development Speakers Terry Tougas , Chair of the International Consortium on Innovation and Quality in Pharmaceutical Development/ IQ Consortium and Gordon Hanson, Chair of the Allotrope Foundation to discuss the current state of data integration into the Pharma industry. Over the next few weeks, we'll be sharing their answers.

This week's featured question is: Tell us what is going on in the pharmaceutical industry right now in data integration that fostered the creation of the IQ Consortium and the Allotrope Foundation?

Gordon: The Allotrope Foundation, as you are all aware and as we see in the media, the harmaceutical industry is really challenged with ways in which to improve its efficiencies. How can we deliver new medicines to patients as economically as possible? In part, that’s due to inefficiency within the industry and ways in which it can handle and manage its data. 

If you look at the analogy with day-to-day life, each of us has better access to data in our personal lives than we do within our own industry, within our own shop and data that we ourselves generate. And this leads to a tremendous inefficiency requiring tedious manual work and re-work of data and documents by highly technical staff, repeated experiments and just overall inefficiencies in how we put together data from disparate functions within our organizations. This is really one of the drivers – maybe the key driver – in the formation of the Allotrope Foundation. How can we make better use of data that we’ve generated and basically do our job much more efficiently than we are doing today?

Terry: I’ll start by saying a couple of words on the IQ side of this. IQ has perhaps a broader scope than just the data. We really were formed around the notion of looking at improvements to drug development in general. So, we span all of that. Obviously, in particular, the data issues are the ones that are very dear to us. In fact, as we’ll hear, it led to Allotrope. But, our real focus is that, in general, as an organization of companies, there are many things that we can address to improve topics and standards and best practices within what I would call the “pre-competitive space”. That’s really what we’re all about. I think that there is a general feeling that there’s a lot of benefit to all the stakeholders. The industry, obviously, but also regulators and ultimately the patients, as well, by getting together in these kinds of forums to discuss these kinds of scientific issues.

To view the rest of the podcast, download it here. 

 Gordon and Terry will both be speakers at this year's Data Driven Drug Development Event. To find out more, download the agenda. If you're interested in joining us January 28-29 in Philadelphia, as a reader of this blog, when you register to join us, mention code XP1715BLOG and save 15% off the standard rate.

Share this article with your social network, just click below to share now!

Share |

IQ Consortium and Allotrope Foundation Discuss Data’s Transformational Role in Pharma!

 Terry Tougas, Chair of the International Consortium on Innovation and Quality in Pharmaceutical Development/IQ Consortium and Gordon Hanson, Chair of the Allotrope Foundation discuss what is going on in the pharmaceutical industry right now to necessitate an event like D4 and how organizations such as the IQ Consortium and the Allotrope Foundation are trying to bring the industry together to standardize data collection and usage.

This podcast includes:

• Can you tell us what is going on in the pharmaceutical industry right now in data integration that fostered the creation of the IQ Consortium and the Allotrope Foundation?
• Each of us has better access to data in our personal lives than we do within our own industry, within our own shop and data that we ourselves generate. And this leads to a tremendous inefficiency requiring tedious manual work and re-work of data and documents….How can we make better use of data that we’ve generated and basically do our job much more efficiently than we are doing today?

For more information about the event download our brochure.

As a reader of the Data-Driven Drug Development (D4) blog, you get a 15% discount off the standard rate when using code XP1715BLOGto to register.. We look forward to seeing you January 28-29 in Philadelphia, PA! If you have any questions about the agenda or event, please contact Kate Devery at kdevery@iirusa.com or visit our webpage.

Wishing you a safe & happy holiday season!
The Data-Driven Drug Development Team
D4 Homepage
D4 Twitter

Share this article with your social network, just click below to share now!

Share |

What can cloud computing do for big data?

While finance, manufacturing, and even government have embraced the potential Big Data presents, the pharmaceutical industry has taken more of a wait and see approach. Recently, given both the overwhelming amount of available data and the fact that traditional pharma approaches to innovation haven’t quite net the results that have been hoped for, a bet on big data for drug development applications makes sense. It’s clear now that the industry tapping into this opportunity.

At Data-Driven Drug Development (D4), pharmaceutical executives as well as a variety of organizations will discuss what they are seeing and what they are doing to take advantage of the data available. In today's featured session, sessions such as, “Using the Cloud – When is the Right Choice?" you will hear how companies are utilizing data to promote drug development.  For more information on this event, taking place January 28-29, 2013, download the agenda.  If you'd like to join us in Philadelphia, register today and mention code XP1715BLOG to save 15% off the standard rate.

Featured Session: Using the Cloud – When Is it the Right Choice?

Featured Speaker: Mollie Shields-Uehling, President and CEO, SAFE-BIOPHARMA

About the Session: Drug development has become a spider web of global relationships, driven in part by the availability of Internet communication. This interconnectedness requires a secure way to transmit data with trust in the identities of the communicating parties and the ability to allow those presenting themselves to online applications to authenticate their identities. Identity, trust and the ability to apply non-repudiable digital signatures to electronic documents, is at the core of unleashing cloud computing for global drug development.

This session will:

• • Discusses the role of identity trust in the drug development process
• • Details an award-winning case study in which cancer researchers for the National Cancer Institute and counterparts at Bristol-Myers Squibb and Sanofi used interoperable digital identities to access, sign and exchange documents involved in the clinical trial start-up process
• • Explains processes and reports on dramatic ROI time and cost savings

Share this article with your social network, just click below to share now!

Share |

TH!NK Big Data for the Future of Pharma

After this election it's safe to say 'Big Data' has become a buzzworthy word. But where to next? Last week, Canada's data warehouse, TH!NK announced it will be merging Business Insights and Big Data.

Employing a state-of-the-art, Oracle-based data warehouse, TH!NK will launch its first offering, TH!NK Sales, in January of 2013. This product will track shipment data from manufacturers and wholesalers to pharmacy outlets and hospitals.

This type of collaboration could potentially produce real time data, trend alerts, efficient verification methods, and the ability to access information from many locations. It will offer valuable insights into sales trends and market share with improved speed, reliability and value. Planned future solutions will include prescribing trends, drug utilization insights and related analysis imperative to stakeholders wishing to forecast, monitor resources and plan drug development.

It is an information economy and the Life Science Industry has an abundance of information. With all of the technological advancements, how will big data change the pharmaceutical industry? And how will it help save time?

Using the powerful analytics to take this information to knowledge is a critical success factor for the industry’s future. How has the information become a key weapon in product development? Join us February 6-8 at the Data Driven Drug Development event where Astrazeneca’s Chief Technology Officer, Angela Yochem keynote session, Weapon of Mass Construction: How Life Science Information Management Facilitates Faster and Better Decision Making. For more information download our full brochure here.

As a reader of this blog, you’ll save 15% off the standard rate when you register to join us and mention code XP1715LINK!

Share this article with your social network, just click below to share now!

Share |

Does Your Company Know How to Create a Data Scientist?

Find, Develop and Retain the Information Management and Analytical Talent for Today’s Data-Driven Environment - Your Questions Answered!

Dan Woods, Forbes.com contributor and Editor of Citoresearch.com will address the challenge of the divide between those who know about the new data and who can monetize its value in the presentation “What Is a Data Scientist? Addressing the Challenge of the Divide between Those Who Know about the New Data and Who Can Monetize its Value”

Angela Yochem, CTO, Astrazenca, David Isom, Head, Information Strategy and Analytics, Pfizer, and Sanjoy Ray, Director, Health IT Strategy, Merck headline a senior-level panel and provide best practices for how they are developing the talent and overcoming challenges in the panel presentation “Where is Everybody? Overcome the Challenges Standing in the Way of Finding the Talent.”

This is just a sample of what our agenda has to offer – download the complete agenda to find out more about the program.

Data-Driven Drug Development will take place January 28-29, 2012 in Philadelphia. As a reader of this blog, you’ll save 15% off the standard rate when you register to join us and mention code XP1715BLOG! If you have any questions about the program, feel free to email Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |

An Invitation to join Data Driven Drug Development from the CIO of Cubist Pharmaceuticals

A few words from Matt Dattilo, CIO, Cubist Pharmaceuticals, the chair for the Data Driven Drug Development Event taking place January 28-29, 2013 in Philadelphia, PA.  If you'd like to join us, register today and mention code P1715BLOG and save 15% off the standard rate!

 

Matt Dattilo, CIO, Cubist Pharmaceuticals

For those of us who work in information management in the pharmaceutical industry, we have seen some major changes in the last few years as the amount of data and our ability to use the data available has grown exponentially -- and will continue to do so. Being able to manage and mine that data more effectively can reduce the cost and length of time to discover and develop new life saving/improving therapies. Therefore, we’re finding we can’t keep the business units and the IT department segregated any longer. Data now has measureable economic value, and so we have seen a shift towards more integrated R&D and IT divisions to take advantage of that value and drive faster and earlier decision making.

It’s an exciting time to be in the pharmaceutical information business.

I would like to invite you to attend IIR’s inaugural Data-Driven Drug Development (D4), taking place on January 28-29 in Philadelphia. As you may have heard, I have the honor of being the chairman for this groundbreaking event and I am truly excited for those in the industry like us to have this opportunity to collaborate on how to bridge the knowledge gap between R&D and IT.

Without a doubt, one of the things that really intrigued me about this program is that the sessions are led by THE leading big pharma executives in the industry. When you download the agenda, you’ll see sessions including:

• Angela Yochem, CTO of Astrazeneca will explain why AZ is on the information management bandwagon, reinventing IT to make it a strategic asset to the business
• Ramzi Najm, Allergan’s VP of Information Technology Management will divulge how he was able to get buy-in from the executive leadership for a data-driven approach to company operations
• Brian Ellerman, Head of Information Solutions at Sanofi-Aventis will discuss strategies to maximize external collaboration through IT

These issues aren’t being addressed anywhere else. For more information about D4, please visit the website.

Thank you very much and I look forward to seeing you in January in Philly!

All the best,

Matt Dattilo,
CIO, Cubist Pharmaceuticals
Chairperson, Data-Driven Drug Development

Share this article with your social network, just click below to share now!

Share |

Making the most of your data

Big Data and analytics seem to be making a big impression on businesses everywhere. With the tools we have today it only makes sense to utilize them for research and development. The real question is, why has is taken so long? The data that has been complied is nothing new, corporations have been doing it for years, but today, many people are now struggling with what to do with this information. And also, how they can transform data to into growth for their company?

McKinsey director David Court says, "What’s the key success factor for exploiting data analytics? From our work—and we’ve probably talked to 100 people—it always comes down to three things: data, models, transformation." Court also states that when compiling data, it's better to address a few problems at a time, rather than try to tackle them all at once. Both data and analytics can help you identify what is really working for your company, which will save both time and money, especially when it comes to identifying what your audience needs.

Join us this January as Daniel Robertson, PhD, Senior Director, LRL IT Research, ELI LILLY, discusses how to structure your unstructured data. The Data-Driven Drug Development event takes place January 28-29 Philadelphia, PA. Download our agenda and subscribe here for news on private industry events, webinars, and the latest information on data-driven drug development.

Share this article with your social network, just click below to share now!

Share |

Announcing IIR’s Data-Driven Drug Development Agenda

Big Data is transforming the way you do business and has the potential to improve R&D productivity, creating HUNDREDS OF BILLIONS OF DOLLARS in value. The data now available and the technologies developed to evaluate it have led to a systematic shift in how IT and R&D function, making the IM organization into a partner with the strategic business side of the industry.

IIR's Data-Driven Drug Development (D4) is the first life science information management event to focus on the strategic business challenges faced by IT and R&D leadership. You will get the knowledge you need to balance new technologies with emerging information disciplines to harness the data available for faster decision making to generate critical information for drug development.

Download the agenda.

Hear from leaders in R&D IT including:

• - Angela Yochem, CTO, Astrazeneca
• - Dan Woods, Contributor, forbes.com, CTO & Editor, citoresearch.com
• - Ramzi Najm , VP, R&D Information & Technology Management, Allergan
• - Matthew Dattillo, CIO, Cubist Pharmaceuticals

Attend D4 to unleash data’s potential to create billions of dollars in revenue and bridge the knowledge gap between R&D and IT:

• • Create a “data scientist” in your organization and overcome the challenge of talent acquisition for the new R&D IT sector
• • Drive scientific and business decisions through data structuring and mining
• • Leverage IT’s rich history of governance and technology introduction to create a framework for external collaboration
• • Integrate and network the growing amounts of data using innovative tools and applications

Data-Driven Drug Development will take place January 28-29, 2012 in Philadelphia. As a reader of this blog, you’ll save 15% off the standard rate when you register to join us and mention code XP1715LINK! If you have any questions about the program, feel free to email Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |